From Yahoo Finance: 2025-06-28 09:25:00

Wedbush analyst Laura Chico lowered the price target on Edgewise Therapeutics (EWTX) to $35 from $40 but maintains an Outperform rating. The FDA deemed CANYON data insufficient for an accelerated filing for sevasemten in Becker muscular dystrophy. Edgewise will explore other avenues to speed up the process and seek full approval with GRAND CANYON. Wedbush still has unanswered questions about sevasemten in DMD, including the patient population to be studied. The news was first reported on TheFly, a source for real-time financial news. For more information on EWTX, visit TipRanks.



Read more at Yahoo Finance: Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush